Table 2. Risks of renal hyperfiltration (RHF) for the development of proteinuria and decline of eGFR.
| Model 1* | Model2 | |||||
|---|---|---|---|---|---|---|
| RR | 95% CI | P | RR | 95% CI | P | |
| Development of proteinuria | ||||||
| RHF | 1.680 | 1.100–2.568 | 0.016 | 1.566* | 1.013–2.420 | 0.044 |
| 30% decline in eGFR | ||||||
| RHF | 3.265 | 1.446–7.372 | 0.004 | 8.720† | 4.205–18.081 | <0.001 |
| 40% decline in eGFR | ||||||
| RHF | 7.962 | 1.421–44.607 | 0.018 | 7.948† | 2.094–30.169 | 0.002 |
* Risks are adjusted by age, sex, and estimated glomerular filtration rate
**Risk is adjusted by age, sex, systolic blood pressure, body mass index, estimated glomerular filtration rate, hemoglobin, monocyte count, aspartate transaminase, aspartate aminotransferase, total cholesterol, diabetes, hypertension, and malignancy.
†Risk is adjusted by age, sex, systolic blood pressure, body mass index, estimated glomerular filtration rate, fasting glucose, hemoglobin, monocyte count, aspartate transaminase, aspartate aminotransferase, alkaline phosphatase, total cholesterol, diabetes, hypertension, coronary artery disease, and malignancy.